Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARZERRA vs BLENREP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
FDA-approved for relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Belantamab mafodotin is likely metabolized via proteolytic degradation into small peptides and amino acids; MMAF is a substrate of CYP3A and P-glycoprotein, but the contribution of CYP3A to clearance is limited.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate.
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
Belantamab mafodotin is highly protein-bound (>99%) to plasma proteins, predominantly to albumin. The released MMAF is also extensively protein-bound (approximately 90% to albumin).
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
The volume of distribution of belantamab mafodotin is approximately 7.8 L (range 4.5-12.4 L), which is slightly greater than plasma volume, indicating limited extravascular distribution. The Vd is not typically normalized to body weight; however, dosing is weight-based (mg/kg) to account for interpatient variability.
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
Blenrep is administered as an intravenous infusion; thus, bioavailability is 100% by the intravenous route. No oral or other routes are approved.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
For moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): reduce dose to 1.9 mg/kg. For severe renal impairment (e GFR 15-29 m L/min/1.73 m²): not recommended. For e GFR <15 m L/min/1.73 m²: contraindicated.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 1.9 mg/kg. Child-Pugh Class C: not recommended.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
Safety and efficacy not established; no specific pediatric dosing guidelines available.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
No specific dose adjustment recommended based on age alone; monitor renal function and consider dose adjustment per renal impairment guidelines.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
WARNING: OCULAR TOXICITY. Blenrep (belantamab mafodotin) causes severe ocular toxicity, including keratopathy and changes in visual acuity, which may require dose modification or discontinuation. Perform ophthalmic exams prior to each dose. Use only in patients who have received at least 4 prior therapies.
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
Ocular toxicity (keratopathy, visual acuity changes),Thrombocytopenia,Infusion-related reactions,Hepatotoxicity (increased transaminases),Embryo-fetal toxicity
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
None known
No known food interactions. Take with or without food.
No specific food interactions known. Maintain adequate hydration.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fetal toxicity and teratogenicity due to the microtubule inhibitor; avoid use unless maternal benefit outweighs risk.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No data on presence in human milk. M/P ratio unknown. Advise to discontinue breastfeeding during treatment and for at least 3 months after last dose due to potential for severe adverse reactions in breastfed infants.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
No specific dose adjustments in pregnancy established. Use is not recommended; if unavoidable, consider dose reduction based on tolerability (e.g., for ocular toxicity). No pharmacokinetic data available to guide adjustments.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
Monitor for ocular toxicity, including keratitis and uveitis; perform ophthalmic exams at baseline and during therapy. Premedicate with corticosteroids and vasoconstrictors to reduce infusion reactions. Blenrep is a BCMA-directed antibody-drug conjugate for relapsed/refractory multiple myeloma. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min).
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
Inform your doctor immediately if you experience blurred vision, eye pain, or light sensitivity.,You will need eye exams before and during treatment.,Report any signs of infusion reactions such as chills, fever, or difficulty breathing.,Use effective contraception during treatment and for 4 months after the last dose.,Avoid driving or operating machinery if you have vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARZERRA vs BLENREP, answered by our medical review team.
ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. BLENREP is a Antineoplastic, Monoclonal Antibody that works by Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARZERRA and BLENREP depend on the specific clinical indication. These are both Antineoplastic, Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. The standard adult dose of BLENREP is: 2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARZERRA and BLENREP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. BLENREP is classified as Category C. FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.